Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Skye Bioscience is a clinical-stage biopharmaceutical company developing cannabinoid-based therapeutics, with lead asset nimacimab (SBI-100 Ophthalmic Emulsion) targeting glaucoma and ocular hypertension through CB1 receptor antagonism. The company operates with zero revenue, burning cash through clinical trials, and trades at 0.9x book value following a 76% decline over the past year. Stock movement is entirely binary, driven by clinical trial readouts, FDA interactions, and capital raises to fund operations.
Skye operates a classic biotech development model: raise capital through equity offerings, deploy funds into clinical trials (Phase 2/3 for nimacimab), seek FDA approval, then monetize through either direct commercialization, licensing deals with major pharma, or acquisition. The CB1 antagonist mechanism differentiates from prostaglandin analogs (current standard of care), potentially commanding premium pricing if efficacy/safety profile proves superior. Current cash runway and 4.77x current ratio suggest 12-18 months of operational funding before next dilutive raise. No pricing power until regulatory approval; valuation entirely speculative based on probability-adjusted net present value of pipeline.
Phase 2/3 clinical trial data releases for nimacimab - primary/secondary endpoint achievement in intraocular pressure reduction
FDA regulatory interactions - IND amendments, meeting outcomes, breakthrough therapy designation potential
Capital raise announcements - dilution concerns given negative cash flow and need for ongoing trial funding
Partnership/licensing deal announcements with established ophthalmology or pharmaceutical companies
Competitive landscape shifts - rival CB1 antagonist programs or novel glaucoma mechanisms entering trials
Binary clinical trial risk - single Phase 3 failure could render equity worthless; ophthalmology endpoints (IOP reduction) are objective but competitive bar is high versus established generics
Regulatory pathway uncertainty - FDA may require additional safety studies for novel CB1 mechanism given historical concerns around systemic cannabinoid effects
Reimbursement risk - payers may resist premium pricing versus $10-20/month generic prostaglandin analogs without compelling differentiation
Established generic competition (latanoprost, timolol) with proven safety profiles and minimal cost creates high efficacy bar for adoption
Pipeline competition from Aerie Pharmaceuticals (Rhopressa/Rocklatan), Allergan/AbbVie next-gen compounds, and other novel mechanisms in development
Acquisition risk by larger pharma could provide exit but at unfavorable valuations given current market cap distress
Dilution risk imminent - 4.77x current ratio suggests adequate near-term liquidity but negative $15-20M annual cash burn requires capital raise within 12-18 months
Going concern risk if trial results disappoint and capital markets remain closed - no revenue cushion to extend runway
Minimal debt provides flexibility but also signals limited institutional confidence for non-dilutive financing
low - Clinical trial timelines and FDA processes operate independently of GDP cycles. However, capital markets access for funding rounds becomes constrained during recessions when risk appetite diminishes, potentially forcing unfavorable dilution or trial delays. Biotech sector correlates weakly with broader economic activity but strongly with risk-on/risk-off sentiment.
High sensitivity through valuation mechanism. Rising rates increase discount rates applied to distant cash flows (potential 2028-2030+ commercialization), compressing NPV of pipeline assets. Higher rates also reduce speculative capital availability for clinical-stage biotechs, widening financing spreads and increasing dilution costs. Fed funds rate directly impacts opportunity cost of holding zero-revenue, cash-burning equities versus risk-free alternatives.
Minimal direct credit exposure given negligible debt (0.01 D/E ratio). However, equity capital markets conditions function as credit proxy - tighter financial conditions reduce ability to raise growth capital through secondary offerings, creating existential funding risk if trials require extension or additional studies.
growth/speculative - Attracts biotech specialists, venture-style equity investors willing to accept binary outcomes for asymmetric upside. High volatility (evidenced by -78.9% six-month return) and zero revenue eliminate value/dividend investors. Momentum traders enter around catalyst dates (trial readouts) but lack fundamental anchor for sustained holding. Institutional ownership likely minimal given micro-cap status and clinical risk.
high - Recent performance shows extreme volatility with -47% quarterly and -79% six-month drawdowns. Clinical-stage biotechs with single-asset concentration exhibit 80-150% annualized volatility, far exceeding broad market. Stock trades on binary event risk rather than earnings fundamentals, creating gap risk around data releases.